CN108392575A - Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine - Google Patents

Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine Download PDF

Info

Publication number
CN108392575A
CN108392575A CN201810539397.XA CN201810539397A CN108392575A CN 108392575 A CN108392575 A CN 108392575A CN 201810539397 A CN201810539397 A CN 201810539397A CN 108392575 A CN108392575 A CN 108392575A
Authority
CN
China
Prior art keywords
huafeng
pills
liao shi
liao
shi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810539397.XA
Other languages
Chinese (zh)
Other versions
CN108392575B (en
Inventor
骆衡
雅科夫·本·大卫
宋玉
李艳梅
潘卫东
杨小生
宋安福
滕彩厚
康宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Wansheng Pharmaceutical Co ltd
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Original Assignee
Guizhou Wansheng Pharmaceutical Co ltd
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Wansheng Pharmaceutical Co ltd, Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences filed Critical Guizhou Wansheng Pharmaceutical Co ltd
Priority to CN201810539397.XA priority Critical patent/CN108392575B/en
Publication of CN108392575A publication Critical patent/CN108392575A/en
Application granted granted Critical
Publication of CN108392575B publication Critical patent/CN108392575B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8884—Arisaema, e.g. Jack in the pulpit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of application of Liao Shi Huafeng pills in preparing anti-leukemia medicine.The inventors found that known Liao Shi Huafeng pills have good inhibiting effect to type of leukemia, provide fundamental basis for the new application of old medicine, the anti-leukocythemia new application to develop Liao Shi Huafeng pills provides new foundation.And Liao Shi Huafeng pills are the Chinese medicine listed, can directly apply to human body and no longer need to carry out clinical safety assessment, can improve the occupation rate of market of this product rapidly.

Description

Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine
Technical field
The present invention relates to a kind of drug research technical field, especially a kind of Liao Shi Huafeng pills are preparing anti-leukemia medicine In application.
Background technology
Liao Shi Huafeng pills, are manufactured by Guizhou Wansheng Pharmaceutical Co., Ltd., pill, can ceases wind antispastic, slit phlegm opens Key.For wind phlegm impatency, hemiplegia, epilepsy, facioplegia, facial paralysis.Main ingredient include Rhizoma Gastrodiae, scorpio, stiff silkworm, The 20 pleasant impression Chinese medicine such as rhizoma typhonii, rhizoma atractylodis, rhizoma arisaematis, Moschus.The vermeil water-bindered pill, section show brown color；There are strong aroma, taste It is pungent.Liao Shi Huafeng pills, century-old secret recipe for existing more than 370 years history of curing the disease, and are carried and are stored in《Zunyi will》、《Zun Yi mansion will》. Liao Shi Huafeng pills were once always that the Qing Dynasty pays tribute the medicine dedicated that imperial physician institute of royal court cures the disease period, there is the title of " emperor's medicine " and " strange medicine ".
Invention content
It is an object of the present invention to be found that Liao Shi Huafeng pills can be used as the application prepared in anti-leukemia medicine.
Technical scheme of the present invention：Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine.(use white blood in vitro Sick cell) and (animal model of leukaemia) detection discovery Liao Shi Huafeng pills have significant leukemia resisting action in vivo, embody The important application of anti-leukemia medicine is gone out can be used as.
Tablet, injection, capsule, oral solution or pill is made in the active ingredient of Liao Shi Huafeng pills.
The Liao Shi Huafeng pills that the present invention uses be according to the standard of Liao Shi Huafeng pills carry out production acquisition with Liao Shiization wind Red active ingredient and the completely the same product of drug effect use existing Liao Shi Huafeng pills.
Due to the adoption of the above technical scheme, the advantage of the invention is that：Inventor is found that Liao Shi Huafeng pills to leukaemia With good inside and outside inhibiting effect, it was found that the new application of this medicine.And Liao Shi Huafeng pills are the drugs listed, it can be directly It no longer needs to carry out clinical safety assessment applied to human body, there is good application prospect, the city of this product can be improved rapidly Field occupation rate.
Description of the drawings
Attached drawing 1 is that Liao Shi Huafeng pills detect the inhibition of different growth of cancer cells；
Attached drawing 2 is that various concentration Liao Shi Huafeng pills detect the inhibition of leukemic cell growth；
Attached drawing 3 is the detection that Liao Shi Huafeng pills treat mouse leukemia.
Specific implementation mode
The embodiment of the present invention：Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine
Inhibit the activity of leukemic cell growth with mtt assay detection Liao Shi Huafeng pills
Cell and other reagents
People's chronic myelogenous leukemia cell strain K562, people red white corpuscle leukaemia cell HEL are Guizhou Province's Chinese science Natural product chemistry key lab of institute preserves.DMEM culture mediums and pancreatin are purchased from Hycone companies, and fetal calf serum (FBS) is purchased from The Zhejiang bio tech ltd Tian Hang, tetramethyl azo mile salt (MTT) are purchased from Solarbio Life Science companies, and two Methyl Asia is soughed (DMSO) and mycillin mixed liquor is purchased from Beijing DingGuo ChangSheng Biology Technology Co., Ltd.Liao Shi Huafeng pills It is provided by Guizhou Wansheng Pharmaceutical Co., Ltd..
It is external to inhibit Leukemia Cell Proliferation
MTT solution is prepared：MTT powder 0.2g are weighed, the PBS 40mL of sterilizing, 60 DEG C of dissolvings, 0.22 μm of filter membrane is added Filtration sterilization, 4 DEG C save backup.
Malignant myeloid cell lines K562, HEL recoveries are taken out from liquid nitrogen container, 5%CO is cultivated in 37 DEG C2With containing 5% in incubator FBS DMEM culture mediums in cultivate.
The cell of logarithmic growth phase respectively, with 2 × 104A/mL density is inoculated in 96 well culture plates, per 190 μ L of hole, is hanged Floating cell 4h dosings, dosing after attached cell 8h.Detect 2 kinds of leukaemia of Liao Shi Huafeng pills pair of 1,2,5,10,20,40 μ g/mL The inhibiting effect of cell growth.Per hole dosing 10 μ L, 37 DEG C, 5%CO248h is cultivated in incubator, and 20 μ L of MTT solution is added (to be protected from light Operation), it is placed in CO2Continue to cultivate 4h in incubator, centrifuge (1500rpm, 8min), discard supernatant liquid, adds 150 μ L per hole DMSO is put into shaking table and rocks (10min, 180rpm, 25 DEG C), with survey OD values (suspension cell 570nm under microplate reader wavelength 490nm Measure), inhibiting rate is calculated, and with prostate proliferative cell BPH1, prostate gland cancer cell PC3, breast cancer cell MDA, melanin Oncocyte WM9 is control,.Each every group 5, cell is parallel.
Result of study shows that 20 μ g/L Liao Shi Huafeng pills only have significantly the growth of two kinds of leukaemia cells HEL, K562 Inhibiting effect (Fig. 1), and there is no significant growth inhibition effect to other cancer cells.Further research various concentration Liao Shi The inhibiting effect (Fig. 2) of two kinds of cell growths of Huafeng pill pair, determines whether its inhibiting effect has concentration dependent and find out IC50 Value.By result it is found that Liao Shi Huafeng pills have a significant concentration dependent to the growth inhibitions of HEL and K562 cells, and according to Its IC50It is worth (K562：9.56 ± 1.35, HEL：12.87 ± 2.12), show that it imitates the growth inhibition of two kinds of leukemia cell lines Fruit is close.From the above data, Liao Shi Huafeng pills have the potential value for developing into anti-leukemia medicine.In addition, research table The bright active ingredient by Liao Shi Huafeng pills prepares piece agent, injection, capsule, oral solution or dripping pill according to above-mentioned experimental data Agent, it may have equally have significant inhibiting effect to the growth of two kinds of leukaemia cells HEL, K562.
Internal leukemia cell proliferation
The structure of animal model：The experimental animal used in the present invention is that Yaacov professors Ben-David send out in the world The bright erythroleukemia mouse model with Friend virus inductions.Friend virus injections can be activated to newborn SCID mice Leukaemia proto-oncogene Fli-1 prevents erythroid differentiation, leads to erythremia (therefore referred to as polycythemia), finally lead Cause mouse spleen increase rupture and it is dead.SCID mice is bought in Shanghai Slac Experimental Animal Co., Ltd., with SPF grades Experimental animal room is raised.The viral supernatants for containing F-MuLV 57 from NIH-3T3 cells are collected and freezed at -80 DEG C.Birth 48h new life SCID mice intraperitoneal inoculation 100mL F-MuLV (clone 57).Point control group and experimental group, control group only use DMSO into Row feeding, experimental group are mixed with feed with Liao Shi Huafeng pills fed respectively, a concentration of 1mg/kg of drug.It feeds to 90 It, tail vein blood drawing, with its specific volume of cell (Hematocrit) of Blood cell analyzer detection；Mouse is put to death, is weighed The weight of its spleen analyzes the effect of its treatment.All zooscopies follow system guide.
Comparative experiments group and control group mice spleen weight, the results showed that control group mice spleen is noticeably greater than experimental group (P <0.01), illustrate that experimental group feeding Liao Shi Huafeng pills significantly have notable therapeutic effect to mouse erythroleukemia；Hematocrit The experimental results showed that the hematocrit of experimental group is noticeably greater than control group (P<0.01), illustrate that feeding Liao Shi Huafeng pills shows and can show Writing reduces the ratio of red blood cell, illustrates that polycythemia is eased.

Claims (2)

1. application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine.
2. application of the Liao Shi Huafeng pills according to claim 1 in preparing anti-leukemia medicine, it is characterised in that：By Liao Tablet, injection, capsule, oral solution or pill is made in the active ingredient of family name's Huafeng pill.
CN201810539397.XA 2018-05-30 2018-05-30 Application of LIAOSHIHUAFENGDAN in preparing anti-leukemia medicine Active CN108392575B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810539397.XA CN108392575B (en) 2018-05-30 2018-05-30 Application of LIAOSHIHUAFENGDAN in preparing anti-leukemia medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810539397.XA CN108392575B (en) 2018-05-30 2018-05-30 Application of LIAOSHIHUAFENGDAN in preparing anti-leukemia medicine

Publications (2)

Publication Number Publication Date
CN108392575A true CN108392575A (en) 2018-08-14
CN108392575B CN108392575B (en) 2021-05-28

Family

ID=63101441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810539397.XA Active CN108392575B (en) 2018-05-30 2018-05-30 Application of LIAOSHIHUAFENGDAN in preparing anti-leukemia medicine

Country Status (1)

Country Link
CN (1) CN108392575B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602859A (en) * 2019-01-18 2019-04-12 贵州省中国科学院天然产物化学重点实验室 Application of the seedling medicine Liao Shi Huafeng pill in preparation prevention and treatment melanoma drug
CN110946948A (en) * 2019-11-28 2020-04-03 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Application of Huafengdan in preparation of anti-breast cancer drugs
CN115336554A (en) * 2022-08-19 2022-11-15 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Construction method of erythroleukemia mouse animal model

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413704A (en) * 2002-11-19 2003-04-30 贵州万胜药业有限责任公司 Huafeng pill

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413704A (en) * 2002-11-19 2003-04-30 贵州万胜药业有限责任公司 Huafeng pill

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐文峰等: "化风丹的研究进展", 《中南药学》 *
高国俊: "对白血病辨证分型及治疗的探讨", 《江苏医药（中医分册）》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109602859A (en) * 2019-01-18 2019-04-12 贵州省中国科学院天然产物化学重点实验室 Application of the seedling medicine Liao Shi Huafeng pill in preparation prevention and treatment melanoma drug
CN109602859B (en) * 2019-01-18 2021-07-16 贵州省中国科学院天然产物化学重点实验室 Application of Miao medicine Liaoshi Huafeng Dan in preparing medicine for preventing and treating melanoma
CN110946948A (en) * 2019-11-28 2020-04-03 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Application of Huafengdan in preparation of anti-breast cancer drugs
CN115336554A (en) * 2022-08-19 2022-11-15 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Construction method of erythroleukemia mouse animal model

Also Published As

Publication number Publication date
CN108392575B (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CN108392575A (en) Application of the Liao Shi Huafeng pills in preparing anti-leukemia medicine
CN103340890A (en) Application of NADPH in preparing medicaments for preventing and treating ischemic cerebral stroke
CN109575100A (en) Glycocholic acid application in preparation of anti-tumor drugs
CN104398526B (en) The application of triptolide and Celastrol in antineoplastic is prepared
CN102727581B (en) A kind of pharmaceutical composition wound to repair
CN102727579B (en) A kind of pharmaceutical composition being used for the treatment of oral ulcer
CN110946948A (en) Application of Huafengdan in preparation of anti-breast cancer drugs
CN104622864B (en) Purposes of the chlorogenic acid in the drug that preparation prevents and treats primary cutaneous T cell lymph cancer
CN102754834A (en) Biological mixture for regulating emotion and relieving stress and preparation method thereof
US9943560B2 (en) Medical compositions containing liquorice extracts with synergistic effect
CN101791363A (en) Broad spectrum anticancer vegetable drug, preparation method and application thereof
CN109602859B (en) Application of Miao medicine Liaoshi Huafeng Dan in preparing medicine for preventing and treating melanoma
KR102032929B1 (en) Radiation sensitizer composition comprising micro RNA-30a and RNA-30b
CN104997787A (en) Application of glycyrrhetinic acid in preparation of anti-radiation product
CN111249274A (en) Application of ginkgolide B in preparation of glioma cell activity inhibitor
CN108403822A (en) The active ingredient application in preparation of anti-tumor drugs of compound capsule for treating stomachache
CN101797242A (en) Application of cysteamine in preparing medicine for treating cancer
JP5786164B2 (en) MET inhibitor containing Mao
CN104491739B (en) It is a kind of to treat medicine of depression and preparation method thereof
CN107929344B (en) Lithospermum compound composition for preventing and treating laryngeal cancer
CN105534999A (en) Pharmaceutical composition for treating tumor and application thereof
CN104840727B (en) Chinese medicine composition with anti-cancer of the esophagus activity and its preparation method and application
CN104645173A (en) Drug for treatment or adjuvant treatment of AIDS (Acquired Immune Deficiency Syndrome), and preparation method and use method thereof
CN102727578A (en) Pharmaceutical composition for healing wounds generated by chemoradiotherapy
CN116211838A (en) Application of 8-gingerol and pharmaceutical composition thereof in treating acute myelogenous leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant